Were cancers diagnosed by the end-of-study biopsy different from cancers found during regular monitoring?
About half of the prostate cancers found during the PCPT were diagnosed at the end-of-study biopsy instead of after a biopsy prompted by a problem with their DRE, an elevated PSA, or symptoms. These men are a very unusual population because most men in the United States would not have a prostate biopsy if they had no signs of cancer from a DRE and a PSA level below 4.0 ng/ml. Additional research will help determine if cancers diagnosed by end-of-study biopsy are different from cancers found during regular monitoring. (See also Question 36.) 23. Did any group of men benefit more from finasteride than others? The reduction in prostate cancer risk from finasteride was seen regardless of age, race/ethnicity, family history of prostate cancer, and PSA level at entry into the study. Research is in progress to determine whether a particular group of men would be more (or less) likely to benefit from finasteride based on other biological and molecular factors. 24. Why was the trial stopped ear
